Trutakna, priced at $425,000 per year, is the first drug approved in the U.S. that targets both BAFF and APRIL proteins ...
In this three-part series, NDTV investigates maternal deaths and severe post-delivery complications reported across ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results